Half-year report · HY
177A.TEDINET S100X2IH
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.5bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥5.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥258m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥380m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥272m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥417m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥274m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥367m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥202m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥795m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥277m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥202m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥277m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥8.8bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥9.1bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥8.5bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.0bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.3bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.8bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥5.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.3bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.4bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥202m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥916m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥518m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥518m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥467m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥220m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥39.53 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥157.57 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥55.7 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 65.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥283m |
| Cell Process Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥536m |
| Cell Process Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥536m |
| Cell Process Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥76m |
| Microbiological Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥686m |
| Microbiological Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥686m |
| Microbiological Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥36m |
| Tissue Culture Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Tissue Culture Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Tissue Culture Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥501m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥2.5bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥2.5bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥541m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥265m |
| Cell Process Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥630m |
| Cell Process Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥630m |
| Cell Process Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥191m |
| Microbiological Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥777m |
| Microbiological Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥777m |
| Microbiological Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥104m |
| Tissue Culture Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Tissue Culture Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Tissue Culture Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥350m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥2.5bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥2.5bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥645m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 480
| Item | Context | Value | Unit |
|---|---|---|---|
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2025-04-01 | |
| Current period end date | FilingDateInstant | 2025-09-30 | |
| Type of current period | FilingDateInstant | HY | |
| Current fiscal year end date | FilingDateInstant | 2026-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Comparative period end date | FilingDateInstant | 2024-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所グロース市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式であり、単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | InterimInstant_No1MajorShareholdersMember | Original text (Japanese)中村 孝人 | |
| Address major shareholders | InterimInstant_No1MajorShareholdersMember | Original text (Japanese)埼玉県坂戸市 | |
| Name major shareholders | InterimInstant_No2MajorShareholdersMember | Original text (Japanese)GOLDMAN SACHS INTERNATIONAL(常任代理人 ゴールドマン・サックス証券株式会社) | |
| Address major shareholders | InterimInstant_No2MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No3MajorShareholdersMember | Original text (Japanese)TAKAコーポレーション株式会社 | |
| Address major shareholders | InterimInstant_No3MajorShareholdersMember | Original text (Japanese)埼玉県坂戸市北大塚518-１ | |
| Name major shareholders | InterimInstant_No4MajorShareholdersMember | Original text (Japanese)オリエンタル酵母工業株式会社 | |
| Address major shareholders | InterimInstant_No4MajorShareholdersMember | Original text (Japanese)東京都板橋区小豆沢３-６-10 | |
| Name major shareholders | InterimInstant_No5MajorShareholdersMember | Original text (Japanese)富士フイルム和光純薬株式会社 | |
| Address major shareholders | InterimInstant_No5MajorShareholdersMember | Original text (Japanese)大阪府大阪市中央区道修町３-１-２ | |
| Name major shareholders | InterimInstant_No6MajorShareholdersMember | Original text (Japanese)コージンバイオ従業員持株会 | |
| Address major shareholders | InterimInstant_No6MajorShareholdersMember | Original text (Japanese)埼玉県坂戸市千代田５-１-３ | |
| Name major shareholders | InterimInstant_No7MajorShareholdersMember | Original text (Japanese)コスモ・バイオ株式会社 | |
| Address major shareholders | InterimInstant_No7MajorShareholdersMember | Original text (Japanese)東京都江東区東陽２-２-20 | |
| Name major shareholders | InterimInstant_No8MajorShareholdersMember | Original text (Japanese)渡辺 恒美 | |
| Address major shareholders | InterimInstant_No8MajorShareholdersMember | Original text (Japanese)東京都港区 | |
| Name major shareholders | InterimInstant_No9MajorShareholdersMember | Original text (Japanese)株式会社SBI証券 | |
| Address major shareholders | InterimInstant_No9MajorShareholdersMember | Original text (Japanese)東京都港区六本木１-６-１ | |
| Name major shareholders | InterimInstant_No10MajorShareholdersMember | Text · Plus | |
| Address major shareholders | InterimInstant_No10MajorShareholdersMember | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |